Predictor | Cohort 1 | Cohort 2 | ||
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Subjects n | 2482 | 10 245 | ||
Blood eosinophil count per 100-cells·µL−1 increase | 0.26 (0.12–0.56) | <0.001 | 0.78 (0.63–0.96) | 0.020 |
Male | 1.53 (1.19–1.98) | 0.001 | 1.15 (1.03–1.29) | 0.016 |
Age per 10 years | 1.24 (1.17–1.32) | <0.001 | ||
Underweight, BMI <18.5 kg·m−2 | 2.29 (1.53–3.43) | <0.001 | 1.41 (1.17–1.70) | <0.001 |
Smoking habits | ||||
Current smoker | 1.74 (1.04–2.91) | 0.034 | ||
Ex-smoker | 1.66 (1.02–2.71) | 0.042 | ||
Cardiovascular disease | 2.18 (1.61–2.95) | <0.001 | ||
COPD exacerbations per 1 increase | 1.12 (1.07–1.17) | <0.001 | 1.09 (1.06–1.12) | <0.001 |
mMRC dyspnoea scale score | ||||
Maximum score | 1.69 (1.05–2.70) | 0.030 | 1.28 (1.06–1.55) | 0.012 |
Missing# | 1.25 (1.06–1.48) | 0.008 | ||
FEV1 % pred | ||||
<30% | 1.36 (1.15–1.62) | <0.001 | ||
Missing# | 1.26 (1.09–1.45) | 0.008 | ||
Triple therapy¶ prescribed | 1.19 (1.05–1.34) | 0.005 |
HR: hazard ratio; BMI: body mass index; mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 s.#: patients without monitoring data; ¶: triple therapy consisted of inhaled corticosteroids, long-acting β2-agonists and long-acting muscarinic antagonists.